Table 8 CSF findings at the time of the first LP and at follow-up LP in group I

Pleocytosis, all

Samples

11/113 (9.7%)

3/15 (20%)

Pleocytosis, B/SC subgroup

Samples

10/92 (10.9%)

2/14 (14.3%)

Pleocytosis, PN/CN/H subgroup

Samples

1/20 (5%)

1/1 (100%)

OCB, all

Samples

2/92 (2.2%)

0/11 (0%)

OCB, B/SC subgroup

Samples

2/75 (2.7%)

0/10 (0%)

OCB, PN/CN/H subgroup

Samples

0/16 (0%)

0/1 (0%)

IgG-IF > 10%, all

Samples

1/104 (1%)

0/11 (0%)

IgG-IF > 10%, B/SC subgroup

Samples

1/83 (1.2%)

0/11 (0%)

IgG-IF > 10%, PN/CN/H subgroup

Samples

0/20 (0%)

Not done

QAlb > Qlim(Alb), all

Samples

51/104 (49%)

7/12 (58.3%)

QAlb > Qlim(Alb), B/SC subgroup

Samples

42/83 (50.6%)

7/12 (58.3%)

QAlb > Qlim(Alb), PN/CN/H subgroup

Samples

8/20 (40%)

Not done

CSF TP elevated, all

Samples

47/104 (45.2%)

7/14 (50%)

CSF TP elevated, B/SC subgroup

Samples

41/87 (47.1%)

7/14 (50%)

CSF TP elevated, PN/CN/H subgroup

Samples

6/16 (37.5%)

Not done

CSF L-lactate elevated, all

Samples

23/96 (24%)

3/13 (23.1%)

CSF L-lactate elevated, B/SC subgroup

Samples

19/80 (23.8%)

3/12 (25%)

CSF L-lactate elevated, PN/CN/H subgroup

Samples

3/15 (20%)

0/1 (0%)

Time since onset of neurological symptoms

Days

5 (0–82)

16 (2–38)